← Back to Search
Use Of A Mouse Lung Challenge Model To Identify Antigens Protective Against Chlamydia Pneumoniae Lung Infection.
A. Murdin, P. Dunn, R. Sodoyer, J. Wang, J. Caterini, R. Brunham, L. Aujame, R. Oomen
Published 2000 · Biology, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Chlamydia pneumoniae is emerging as a significant human pathogen. Infection causes a range of respiratory tract diseases and is associated with atherosclerosis. A vaccine could provide a considerable public health benefit; however, antigens able to elicit a protective immune response are largely unknown. A panel of open-reading frames (ORFs) from the C. pneumoniae genome sequence was screened for ability to elicit protective responses. Balb/c mice immunized with DNA containing the ORFs were tested for their ability to limit lung infection following an intranasal challenge. Immunization with DNA encoding the major outer membrane protein or an ADP/ATP translocase (Npt1(Cp)) of C. pneumoniae resulted in a reduced bacteria load in the lung after challenge. The identification of these antigens as protective is a significant step toward development of a C. pneumoniae vaccine and demonstrates the feasibility of using a DNA immunization strategy to screen the C. pneumoniae genome for other protective ORFs.
This paper references
SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTION
P. Saikku (1988)
A NEW RESPIRATORY TRACT PATHOGEN: CHLAMYDIA PNEUMONIAE STRAIN TWAR
J. T. Grayston (1990)
Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.
D. Hahn (1991)
Interaction of chlamydiae and host cells in vitro.
J. Moulder (1991)
Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease.
D. Thom (1992)
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.
P. Saikku (1992)
Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques.
A. Shor (1992)
Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain.
C. C. Kuo (1993)
Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries.
C. C. Kuo (1993)
Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis.
J. T. Grayston (1993)
Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection.
L. Allegra (1994)
Isolation and characterization of a gene encoding a Chlamydia pneumoniae 76-kilodalton protein containing a species-specific epitope
M. Perez Melgosa (1994)
Chlamydia pneumoniae (TWAR)
C. Kuo (1995)
The immunobiology and immunopathology of chlamydial infections
M. E. Ward (1995)
Poxvirus‐based vaccine candidates for cancer, AIDS, and other infectious diseases
Marion E. Perkvs (1995)
Isolation of Chlamydia pneumoniae from the Coronary Artery of a Patient with Coronary Atherosclerosis
Julio Ramirez (1996)
Chlamydia pneumoniae and chronic lung diseases.
A. Laurila (1997)
Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1.
N. Ishii (1997)
DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection.
D. Zhang (1997)
Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction.
C. C. Kuo (1997)
HIV‐1‐specific cell‐mediated immune responses induced by DNA vaccination were enhanced by mannan‐coated liposomes and inhibited by anti‐interferon‐γ antibody
S. Toda (1997)
Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery.
B. Chiu (1997)
Mucosal immunization with DNA-liposome complexes.
L. Klavinskis (1997)
Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of Chlamydia pneumoniae
M. Wiedmann-Al-Ahmad (1997)
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen.
L. Jackson (1997)
Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma.
D. Hahn (1998)
Chlamydia pneumoniae and cardiovascular disease.
L. Campbell (1998)
Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles
Shing C. Chen (1998)
Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease.
M. Maass (1998)
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
J. Schneider (1998)
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.
M. Sedegah (1998)
Local Immune Responses to Chlamydia pneumoniae in the Lungs of BALB/c Mice during Primary Infection and Reinfection
Jenni M. Penttilä (1998)
Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus
S. Kent (1998)
Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers
R. Belshe (1998)
Identification of Two Novel Genes Encoding 97- to 99-Kilodalton Outer Membrane Proteins of Chlamydia pneumoniae
K. Knudsen (1999)
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
D. Salmon-Céron (1999)
Two Nucleotide Transport Proteins in Chlamydia trachomatis, One for Net Nucleoside Triphosphate Uptake and the Other for Transport of Energy
J. Tjaden (1999)
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
T. Evans (1999)
Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice.
M. Rottenberg (1999)
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
H. Robinson (1999)
Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain
Depletion of CD8+ cells abolishes memory in acquired immunity against Chlamydia pneumoniae in BALB/c mice
Comparative genomes of Chlamydia pneumoniae and C. trachomatis
S. Kalman (1999)
[Community acquired pneumonia].
T. Marrie (2001)
This paper is referenced by
Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles
Rajnish Sahu (2018)
Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions.
D. Pedicino (2013)
Vaccination against chlamydial and mycobacterial infections Ph
Á. Szabó (2013)
Chlamydia Vaccine Development
J. Igietseme (2013)
DNA Vaccines against Bacterial Pathogens
M. Chambers (2013)
In Vivo Chlamydial Infection
R. Rank (2012)
Chlamydia vaccine: progress and challenges.
A. Murthy (2012)
Comprehensive analysis of the impact of endemic Chlamydia pecorum infection in cattle
Anil Poudel (2012)
J. Igietseme (2012)
Chlamydia vaccines: recent developments and the role of adjuvants in future formulations
J. Igietseme (2011)
Vaccination with DNA vector expressing chlamydial low calcium response protein E (LcrE) against Chlamydophila pneumoniae infection.
Ildikó Faludi (2011)
Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunization.
Y. Li (2010)
Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis
J. Deniset (2010)
Innate immunity and vaccines in chlamydial infection with special emphasis on Chlamydia pneumoniae.
M. Puolakkainen (2009)
Chlamydia vaccine candidates and tools for chlamydial antigen discovery
D. Rockey (2009)
Genital tract CD4 + T cells for vaccination and protection against Chlamydia trachomatis
Ellen Marks (2009)
Role of Chlamydia pneumoniae in atherosclerosis.
C. Watson (2008)
Chlamydophila pneumoniae inhibits differentiation of progenitor adipose cells and impairs insulin signaling.
Y. Shi (2008)
Chlamydia trachomatis infection: host immune responses and potential vaccines
L. Hafner (2008)
Therapeutic vaccines against chlamydial diseases
Y. Li (2008)
Immunity Against Chlamydia trachomatis
E. Marks (2008)
Live‐attenuated influenza viruses as delivery vectors for Chlamydia vaccines
Q. He (2007)
Reducing the risk of Chlamydia trachomatis transmission: male circumcision or a female vaccine?
L. Hafner (2007)
Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection.
Callum Thorpe (2007)
Mouse model of respiratory Chlamydia pneumoniae infection for a genomic screen of subunit vaccine candidates.
D. Li (2006)
Combination vaccines: design strategies and future trends
J. Igietseme (2006)
Experimental Chlamydia pneumoniae infection model: Effects of repeated inoculations and treatment
L. Törmäkangas (2006)
Innate immune responses induced by Chlamydia pneumoniae infection
V. Magdalenić (2005)
Maternal Genital Tract Infection and the Neonate
D. Tristram (2005)
PULMONAR Y INFECTION A ND A T HEROSCLEROSIS IN A N EXPERIMENT A L CHLAMYDIA PNEUMONIAE MODEL
L. Erkkilä (2005)
Vaccines Against Chlamydia pneumoniae: Can They Be Made?
M. Rottenberg (2005)
CD8+ T Cell Response in Experimental Chlamydia pneumoniae Infection
A. Tammiruusu (2005)See more